10.82

5.34% -0.61

Ginkgo Bioworks Holdings Inc (DNA)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt DNA? Forum Prognose

Schlusskurs vom Vortag:

$11.43

Offen:

$11.7

24-Stunden-Volumen:

2.02M

Relative Volume:

1.30

Marktkapitalisierung:

$621.92M

Einnahmen:

$217.11M

Nettoeinkommen (Verlust:

$-651.19M

KGV:

-0.8329

EPS:

-12.99

Netto-Cashflow:

$-387.26M

1W Leistung:

-26.54%

1M Leistung:

-6.56%

6M Leistung:

+16.22%

1J Leistung:

-79.03%

1-Tages-Spanne:

$10.81

$12.26

1-Wochen-Bereich:

$10.81

$15.96

52-Wochen-Spanne:

$5.26

$64.40

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Firmenname

Ginkgo Bioworks Holdings Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(877) 442-5362

Adresse

27 DRYDOCK AVENUE, BOSTON

Mitarbeiter

1,218

Twitter

Nächster Verdiensttermin

2024-08-08

Neueste SEC-Einreichungen

DNA's Discussions on Twitter

Vergleichen Sie DNA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DNA Ginkgo Bioworks Holdings Inc	10.82	621.92M	217.11M	-651.19M	-387.26M	-12.99
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-15	Herabstufung	BTIG Research	Neutral → Sell
2024-05-10	Herabstufung	William Blair	Mkt Perform → Underperform
2023-11-14	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-11-09	Herabstufung	BTIG Research	Buy → Neutral
2023-06-02	Herabstufung	Goldman	Neutral → Sell
2023-05-11	Herabstufung	William Blair	Outperform → Mkt Perform
2022-11-29	Eingeleitet	Berenberg	Buy
2022-10-04	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-18	Herabstufung	BofA Securities	Neutral → Underperform
2022-03-02	Fortgesetzt	Cowen	Outperform
2022-02-23	Eingeleitet	Goldman	Neutral
2022-02-01	Eingeleitet	BofA Securities	Neutral
2022-01-28	Eingeleitet	BofA Securities	Buy
2022-01-07	Eingeleitet	BTIG Research	Buy
2021-11-29	Eingeleitet	Jefferies	Buy
2021-10-13	Eingeleitet	Raymond James	Outperform
2021-10-12	Eingeleitet	William Blair	Outperform
2021-09-20	Eingeleitet	HSBC Securities	Buy

Alle ansehen

Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten

Feb 21, 2025

Volta Labs enhances Ginkgo Bioworks sequencing workflow By Investing.com - Investing.com Canada

Feb 21, 2025

Ginkgo Bioworks Integrates Callisto For Difficult-To-Automate Ngs Processes In Their High-Throughput Lab - Marketscreener.com

Feb 21, 2025

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab - Marketscreener.com

Feb 21, 2025

Can This New Lab Automation System Transform Ginkgo's DNA Sequencing Capabilities? - StockTitan

Feb 21, 2025

Short Interest in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Rises By 5.4% - MarketBeat

Feb 21, 2025

Ginkgo Bioworks (DNA) to Release Earnings on Tuesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Ginkgo Bioworks Partners With HaDEA on Up to $25.1 Million Project for Rapid Virus Diagnostics - Marketscreener.com

Feb 20, 2025

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - PR Newswire

Feb 20, 2025

Ginkgo Bioworks (NYSE:DNA) Shares Down 6.3%Time to Sell? - MarketBeat

Feb 20, 2025

Feb 19, 2025